# Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

> **NCT05756166** · PHASE1,PHASE2 · TERMINATED · sponsor: **Roswell Park Cancer Institute** · enrollment: 5 (actual)

## Conditions studied

- Anatomic Stage IV Breast Cancer AJCC v8
- Metastatic Triple-Negative Breast Carcinoma
- Unresectable Triple-Negative Breast Carcinoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Celecoxib
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Interferon Alpha-2
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Rintatolimod

## Key facts

- **NCT ID:** NCT05756166
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-02-16
- **Primary completion:** 2025-04-08
- **Final completion:** 2025-06-19
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Funding ended
- **Last updated:** 2025-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05756166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05756166, "Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05756166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*